GlycoEra is positioned as the leading precision protein degradation company. Bifunctional biologics (G-LyTACs), designed by our novel and proprietary technology bind to disease-causing proteins and transport them to the lysosome using naturally occurring endocytic receptors. The disease-causing proteins are degraded in the lysosome and removed from the body. Unlike intracellular protein degraders, like PROTACs and molecular glues, our technology can access targets that are extracellular and membrane proteins, thereby opening up novel targets and therapeutic areas for intervention.
Company Details
- Employees
- 36
- Founded
- -
- Address
- Einsiedlerstrasse 34, Wädenswil,zurich 8820,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.glycoera.com
- HQ
- Wädenswil, Zurich
Glycoera Ag Questions
Glycoera Ag's website is http://www.glycoera.com
Glycoera Ag's LinkedIn profile is https://ch.linkedin.com/company/glycoera-ag
Glycoera Ag has
36 employees.
View email and phone details for 36
employees at Glycoera Ag.
Glycoera Ag's industry is
Biotechnology Research
Glycoera Ag's top competitors are
Numab Therapeutics Ag,
Alentis Therapeutics,
Araris Biotech Ag,
Synendos Therapeutics Ag,
Noema Pharma,
Muvon Therapeutics Ag,
Immunos Therapeutics Ag,
Haya Therapeutics,
Limmatech Biologics Ag,
Windward Bio.
Glycoera Ag's categories are Biotechnology Research
Glycoera Ag's founding year is 2020
